Overview

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Status:
Completed

Trial end date:
2021-03-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate clinical efficacy of rozanolixizumab as a treatment for subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Phase:

Phase 2

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Treatments:

Rozanolixizumab